Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 12Other hematologic neoplasm 9Gastrointestinal 7Myeloid 5Gynecologic 5Genitourinary 5Tumor-Agnostic 2CNS 2Head & Neck 1

Conditions

Neoplasms 1Neoplasm, Residual 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tyrosine Kinase Inhibitors × Tumor-Agnostic × Clear all
NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
82 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT01098500 2017-05-30

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

GlaxoSmithKline

Completed
3,800 enrolled 19 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡